Search company, investor...


Founded Year



Acquired | Acquired

Total Raised






About BioVex

BioVex is a biotechnology company that develops vaccines. The company develops vaccines for the treatment of cancer and chronic infectious diseases. BioVex has two proprietary vaccine platforms; OncoVEX and ImmunoVEX, and a functional genomics platform for gene target validation in neurons and other tissues.

Headquarters Location

34 Commerce Way

Woburn, Massachusetts, 01801,

United States


Missing: BioVex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioVex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioVex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioVex is included in 2 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

BioVex Patents

BioVex has filed 10 patents.

The 3 most popular patent topics include:

  • Animal viral diseases
  • Animal virology
  • Viral diseases
patents chart

Application Date

Grant Date


Related Topics




Biotechnology, Molecular biology, Virology, Transcription factors, Cytokines


Application Date


Grant Date



Related Topics

Biotechnology, Molecular biology, Virology, Transcription factors, Cytokines



Latest BioVex News

Insights on the Oncolytic Virus Immunotherapy Global Market to 2028 - Featuring Key Players AdCure Bio, BioVex, Calidi Biotherapeutics, Takara Bio and Others

Dec 13, 2022

The global cancer immunotherapy market encompasses a broad range of applications, in which oncolytic virus immunotherapy is playing a vital role in overall development. Report Highlights Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028 Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials Patent Information On More Than 60 Therapies in Clinical Trials IMLYGIC, Oncorine, Delytact: Availability, Dosage, and Price Analysis Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment Oncolytic Virus Immunotherapy Application By 10 Cancer Recent Strategic Partnerships, Collaborations, Mergers and Acquisitions The therapy involves a very basic thread of using viruses for targeting cancer cells and harnessing the natural as well as the destructive power of the immune system against the cancer cells. In a very short period of time, the clinical outcome associated with the therapy has laid down the foundation for the over-achieving future of the therapy. The therapy market is estimated to get recognized as a necessity in the overall cancer therapeutics market where old and traditional therapies available are not successful in declining the increasing mortality rate across the globe. Researchers have been successful in modifying the basic immunotherapy strategy by introducing the benefits of viruses in targeting the host cells. Beyond the excellent capacity of the virus to get incorporated into the host cell, the therapeutic introduction of the virus in cancer therapeutics is providing enormous amounts of opportunities that were somehow lacking in the overall cancer therapeutics market for a prolonged period of time. The future approval of the oncolytic virus therapy against a wide range of cancer types is believed to strengthen the pharmaceutical industry to reach the revenue sales that have not been recorded for any of the cancer therapy drugs. The strong link of the therapy with the clinical pipeline and the future timeframe which is about to justify the applications of the therapy are observed to overcome the challenges that the researchers have been facing in terms of resistance development, off-targeting, and adverse side effects. Amid the growth of other cancer therapies in the cancer therapeutics market, oncolytic virus therapy soon is going to deliver significant revolution and growth. The unimaginable applications of the therapy and the orientation of the government bodies towards expanding the clinical trial market of the same is estimated to develop the market as a dominant one for millions of patients who haven't received any benefits from the available therapies. The entry of oncolytic virus therapy into the market horizon is estimated to provide enormous healthcare opportunities to patients who have been struggling with cancer for a prolonged period of time. As per the report findings, the overall appreciation that the therapy has achieved in the such a shorter time period is poised to incline the therapy towards substantial growth. In the coming time period, the therapy market is believed to deliver promising trends and opportunities for researchers working in different biopharmaceutical companies and research centers, with hundreds of driving forces driving the market through various complications. On the regulatory side, the legislations of developed pharmaceutical countries are also inclining towards boosting the researchers to expand the market applications and drive the competition in the right direction, where appropriate funds for clinical research activities are acting as the catalyst for the therapy. The unlimited applications found within the therapy and the clinical platform for the same is estimated to move the therapy toward success at an unprecedented rate in the coming years. Key Topics Covered: 2. Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses Towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.3 Viral Oncolysis Mechanism of Action 3. Oncolytic Viruses Immunotherapy Overview 3.1 Stimulation of Antitumor Immune Responses 3.2 Oncolytic Viruses as Cancer Vaccines 4. Potential Oncolytic Virus Immunotherapy for Cancers 4.1 Breast Cancer 11.1 Estrella Biopharma Signs Deal To Merge With Blank Check Company 11.2 ABL and Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase 11.3 TILT Biotherapeutics and Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer 11.4 Virogin Biotech and MD Anderson Announce Strategic Collaboration For Treating Advance Cancers 11.5 ABL Signs Pact With KaliVir On Oncolytic Viruses 11.6 Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial 11.7 KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses 11.8 ImmVira and Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy 11.9 Calidi and Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies 11.10 Synthetic Biologics Completes Acquisition of VCN Biosciences 11.11 VacV Biotherapeutics Exits Stealth With $3 Million Investment 11.12 Targovax Enters Research Collaboration With Karolinska Institutet Professor 11.13 Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors 11.14 Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics 11.15 Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery 11.16 Imugene and Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination 11.17 CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination 11.18 Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors 12. Global Oncolytic Virus Immunotherapy Market Dynamics 12.1 Favorable Market Parameters

BioVex Frequently Asked Questions (FAQ)

  • When was BioVex founded?

    BioVex was founded in 1997.

  • Where is BioVex's headquarters?

    BioVex's headquarters is located at 34 Commerce Way, Woburn.

  • What is BioVex's latest funding round?

    BioVex's latest funding round is Acquired.

  • How much did BioVex raise?

    BioVex raised a total of $155.36M.

  • Who are the investors of BioVex?

    Investors of BioVex include Amgen, Sectoral Asset Management, MVM Partners, Morningside Ventures, Ventech and 25 more.

  • Who are BioVex's competitors?

    Competitors of BioVex include Hawaii Biotech, PDS Biotechnology, PaxVax, Raptor Pharmaceutical Corp., Variation Biotechnologies and 14 more.

Compare BioVex to Competitors

Zetra Biologicals

Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Altimmune Logo

Altimmune (NASDAQ: ALT) offers immunotherapeutic solutions focused on the development of products to stimulate immune responses for the prevention and treatment of diseases. Its product pipeline includes peptide-based GLP-1/glucagon dual receptor agonists used for the treatment of obesity and non-alcoholic steatohepatitis and immunotherapeutics for chronic hepatitis B (CHB) infections. The company was founded in 1997 and is based in Gaithersburg, Maryland.


SensiGen is a biotechnology company. They specialize creating tests to screen for diseases more efficiently and quickly. Their goal is to lower the overall costs of diagnosing serious diseases, usually ones where not many diagnostic tests exist.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.